


Amendments to the Claims:

Listing of Claims:

Claim 1 (original): A compound of formula (I):



wherein

each of x and y is, independently of the other, 0 or 1;

R₁ is an organic moiety that can be bound to nitrogen;

X is C=O (especially preferred) or C=S with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond and with the proviso that then y is 1 and R is hydrogen or an organic moiety that can be bound to nitrogen, or

X is (CR₇), wherein R₇ is hydrogen or an organic or inorganic moiety with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero or y is 1 and then -R is →O; and

each of R₂, R₃, R₄, R₅ and R₆, independently of the others, is an organic moiety or hydrogen or an inorganic moiety, with the proviso that R₃ cannot be unsubstituted phenyl unless R₁ is phenyl substituted with a heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

Claim 2 (original): A compound according to Claim 1,

wherein

each of x and y is, independently of the other, 0 or 1;

R₁ is substituted or unsubstituted aryl or heteroaryl, especially phenyl, which is substituted with up to 4 substituents, preferably up to 3 substituents, where the substituents are the same or different and are independently selected from halo,

e.g., F or Cl; C₁-C₇lower alkyl which may be unsubstituted or substituted with halo, especially methyl, ethyl, propyl or trifluoromethyl; cyano; cyano-lower alkyl, e.g., cyanomethyl, cyanoethyl or cyanopropyl; lower alkoxy; amino; amino-lower alkyl; amino-lower alkoxy; amino-lower alkyl sulfanyl; or thiol-lower alkyl, wherein the amino group can be mono- or di-substituted, e.g., -(C₁-C₇)_mNR₈R₉ or -O-(C₁-C₇)_mNR₈R₉,

wherein

m is 0 or 1; and

R₈ and R₉ can be the same or different and are independently H; lower alkyl, e.g., methyl, ethyl or propyl; lower cycloalkyl, e.g., cyclopropyl, or

R₈ and R₉, together with the N atom, form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., azetidiny, pyrrolidiny, piperidino, morpholiny, imidazoliny, imidazoliny-ethyl, piperaziny or lower alkyl-piperaziny; amino-carbonyl-lower alkyl, e.g., R₈R₉-N-C(O)-CH₂-, wherein R₈ and R₉ are as defined above; heterocyclyl; heterocyclyl-lower alkyl; heterocyclyl-lower alkoxy; or heterocyclyl-lower alkanesulfanyl, wherein the heterocyclyl is a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazolyl, imidazoliny, pyrrolidiny, morpholiny, azetidiny, pyridyl, piperidino, piperidyl, piperaziny or lower alkyl-piperaziny; substituted or unsubstituted amide; amide-lower alkyl, e.g., -CH₂-CH(NH₂)-C(O)-NH₂), wherein alkyl may be linear or cyclic, e.g., cyclopropylene; and the alkyl in any of the substituents above may optionally be substituted with -NR₈R₉, wherein R₈ and R₉ are as defined above;

X is C=O or C=S, with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond and with the proviso that then y is 1 and R is hydrogen or an organic moiety that can be bound to nitrogen, or

X is (CR₇), wherein R₇ is hydrogen or an organic moiety, such as C₁-C₇lower alkyl; amino; or amino alkyl, wherein the alkyl may be unsubstituted or substituted with halo, e.g., methyl, ethyl, propyl or trifluoromethyl; lower alkoxy, e.g., methoxy; or cycloalkyl, e.g., cyclopropyl; with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond; and with the proviso that then y is zero, or y is 1 and then -R is →O;

R₂ is hydrogen;

R₃ is unsubstituted or substituted C₅-C₁₄heterocyclyl, e.g., thienyl, benzo[1,3]dioxolo, indolyl, benzofuranyl or pyridiyl; unsubstituted or substituted C₅-C₁₄aryl, e.g., phenyl or phenyl substituted with up to 4 substituents, preferably up to 3 substituents, which are the same or different and are selected from halo, e.g., Cl or F; hydroxy; C₁-C₄lower alkoxy, e.g., methoxy; lower alkyl, e.g., methyl; or -(C₁-C₄)_mNR₈R₉,

wherein

m is 0 or 1; and

R₈ and R₉, are as defined above, e.g., piperaziny, methylpiperaziny, morpholinyl or pyrrolidinyl;

R₄ is hydrogen or halo, e.g., fluoro or chloro;

R₅ is hydrogen; and

R₆ is hydrogen, amino, amino alkyl or alkylamido, e.g., methylamido -NHC(O)-CH₃), with the proviso that R₃ cannot be unsubstituted phenyl unless R₁ is phenyl substituted with an heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

Claim 3 (original): A compound according to Claim 1,

wherein

each of x and y is, independently of the other, 0 or 1;

R₁ is substituted or unsubstituted phenyl where the phenyl is substituted with up to 4 substituents, preferably up to 3 substituents, where the substituents are the same or different and are independently selected from halo, e.g., F or Cl; C₁-C₇lower alkyl, which may be unsubstituted or substituted with halo, especially methyl, ethyl, propyl or trifluoromethyl; cyano; cyano-lower alkyl, e.g., cyanomethyl, cyanoethyl or cyanopropyl; amino; amino-lower alkyl, wherein the amino group can be mono- or di-substituted, e.g., -(C₁-C₇)_mNR₈R₉ or -O-(C₁-C₇)_mNR₈R₉,

wherein

m is 0 or 1; and

R₈ and R₉ can be the same or different and are independently H; lower alkyl, e.g., methyl, ethyl or propyl; lower cycloalkyl, e.g., cyclopropyl, or

R₈ and R₉, together with the N atom, form a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazolinyl, imidazolinyl-ethyl, piperaziny or lower alkyl-piperaziny; amino-carbonyl-lower alkyl, e.g., R₈R₉-N-C(O)-CH₂-, wherein R₈ and R₉ are as defined above; heterocyclyl; heterocyclyl-lower alkyl; heterocyclyl-lower alkoxy; or heterocyclyl-lower

alkanesulfanyl, wherein the heterocyclyl is a 3- to 8-membered heterocyclic ring containing 1-4 nitrogen, oxygen or sulfur atoms, e.g., imidazoliny, imidazoliny, imidazoliny-ethyl, piperaziny or lower alkyl-piperaziny; substituted or unsubstituted amide; amide-lower alkyl, e.g., -CH₂-CH(NH₂)-C(O)-NH₂, wherein alkyl may be linear or cyclic, e.g., cyclopropylene; and the alkyl in any of the substituents above may optionally be substituted with -NR₈R₉, wherein R₈ and R₉ are as defined above;

X is (CR₇), wherein R₇ is hydrogen; lower alkyl, e.g., methyl or ethyl; amino; or amino alkyl, with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero, or y is 1 and then -R is →O;

R₂ is hydrogen;

R₃ is unsubstituted or substituted C₅-C₁₄heterocyclyl, e.g., thienyl, benzo[1,3]dioxolo, indolyl, benzofuranyl or pyridyl; unsubstituted or substituted C₅-C₁₄aryl, e.g., phenyl or phenyl substituted with up to 4 substituents, preferably up to 3 substituents, which are the same or different and are selected from halo, e.g., Cl or F; hydroxy; C₁-C₄lower alkoxy, e.g., methoxy; lower alkyl, e.g., methyl; or -(C₁-C₄)_mNR₈R₉, wherein

m is 0 or 1; and

R₈ and R₉ are as defined above, e.g., piperaziny, methylpiperaziny, morpholiny or pyrrolidiny;

R₄ is hydrogen or halo, (e.g. fluoro or chloro);

R₅ is hydrogen; and

R₆ is hydrogen, with the proviso that R₃ cannot be unsubstituted phenyl unless R₁ is phenyl substituted with an heterocyclic ring;

or a pharmaceutically acceptable salt thereof.

Claim 4 (currently amended): A pharmaceutical composition comprising a compound of formula (I), according to ~~any of Claims 1-3~~Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Claim 5 (currently amended): A compound of the formula (I), according to ~~any one of Claims 1-3~~Claim 1, for use in the treatment of the animal or human body, especially in the treatment of a protein kinase dependent disease.


Claim 6 (original): A compound according to Claim 5, wherein the protein kinase dependent disease is preferably one depending on PKB, ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) PKB, ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the PKB, ALK, S6K1 or RET pathways, or a disease dependent on any two or more of the kinases just mentioned.

Claims 7-9 (cancelled)

Claim 10 (currently amended): A method of treatment of a disease that responds to inhibition of a protein kinase, which comprises administering a prophylactically or especially therapeutically effective amount of a compound of formula (I) according to ~~any one of Claims 1-3~~Claim 1, or a pharmaceutically acceptable salt thereof, to a warm-blooded animal, e.g., a human, in need of such treatment.

Claim 11 (original): A method according to Claim 10, wherein the disease to be treated is a proliferative disease, preferably a benign or especially malignant tumor, more preferably carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancreas, lung, vagina, thyroid, sarcoma, glioblastomas, multiple myeloma, gastrointestinal cancer, colon carcinoma, colorectal adenoma, tumor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, especially of epithelial character, mammary carcinoma, leukemia, metabolic diseases, type II diabetes, obesity, hyperlipidemia and atherosclerosis.

Claim 12 (original): A compound according to formula (I), for use in the treatment of a protein kinase dependent disease, especially one depending on ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the ALK, S6K1 or RET pathways or disease comprising administering a compound according to formula (I)



wherein

each of x and y is, independently of the other, 0 or 1;

R₁ is an organic moiety that can be bound to nitrogen;

X is C=O, especially preferred or C=S, with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond and with the proviso that then y is 1 and R is hydrogen or an organic moiety that can be bound to nitrogen, or

X is (CR₇), wherein R₇ is hydrogen or an organic or inorganic moiety with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero or y is 1 and then -R is →O; and

each of R₂, R₃, R₄, R₅ and R₆, independently of the others, is an organic moiety or hydrogen or an inorganic moiety;

or a pharmaceutically acceptable salt thereof.

Claim 13 (original): A compound according to Claim 12, comprising a the compound of the formula (I), or a pharmaceutically acceptable salt thereof,

wherein

each of x and y is, independently of the other, 0 or 1;

R₁ is phenyl or phenyl-lower alkyl, each of which, in the phenyl moiety, is unsubstituted or substituted by up to three moieties independently selected from halogen, especially fluoro, chloro, bromo or iodo; lower alkyl, especially methyl or ethyl; halo-lower alkyl, especially trifluoromethyl; hydroxy; lower alkoxy, especially methoxy; C₆-C₁₄aryl, especially phenyl; hydroxy-lower alkyl, especially 2-hydroxyethyl or hydroxymethyl; amino; amino-lower alkyl, especially aminomethyl or 2-aminoethyl; amidino; *N*-hydroxy-amidino; amidino-lower alkyl, such as 2-amidinoethyl; *N*-hydroxyamidino-lower alkyl, especially *N*-hydroxy-amidino-methyl or -2-ethyl; cyano-lower alkyl, especially cyanomethyl; and cyano or is C₃-C₈cycloalkyl, especially cyclohexyl; or hydroxyC₃-C₈cycloalkyl, especially hydroxy-cyclohexyl;

X is C=O or C=S, with the proviso that then the dashed line bonding X to N is absent, so that X is bound to the adjacent N via a single bond, and with the proviso that then y is 1 and R is hydrogen; lower alkyl, especially methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, 2,2-dimethylpropyl or 2-ethyl-*n*-butyl; mono- or di-hydroxy-lower alkyl, especially 2,3-dihydroxy-propyl or 3-hydroxy-2,2-dimethylpropyl; C₆-C₁₄aryl, which is unsubstituted or substituted by 1-3 substituents selected from lower alkyl, especially methyl or ethyl; halo-lower alkyl, especially trifluoromethyl; halogen, especially chloro; amino; lower alkanoylamino; lower alkoxy, especially methoxy and

nitro; C₃-C₈cycloalkyl, especially cyclopropylmethyl or cyclohexylmethyl; or furanyl-lower alkyl, especially 3-furanyl-methyl, or

X is (CR₇), wherein R₇ is hydrogen or an organic or inorganic moiety that can be bound to nitrogen with the proviso that then the dashed line bonding X to N is a bond, so that X is bound to the adjacent N via a double bond, and with the proviso that then y is zero, or y is 1 and then -R is →O;

R₂ is hydrogen;

R₃ is hydrogen; lower alkyl, especially ethyl; halo, especially fluoro, chloro or bromo; lower alkoxy, especially methoxy; or unsubstituted or substituted C₆-C₁₄aryl, especially phenyl, hydroxyphenyl or methoxyphenyl;

R₄ is hydrogen or halo, especially chloro;

R₅ is hydrogen or lower alkoxy, especially *n*-lower hexyloxy; and

R₆ is hydrogen, halo, especially chloro; C₆-C₁₄aryl, especially phenyl; C₃-C₈cycloalkyl, especially cyclopropyl; amino; lower alkyl-amino, especially methylamino or *n*-butylamino; hydroxy-lower alkylamino, especially 2-hydroxyethyl-amino; or C₆-C₁₄arylcarbonylamino, especially benzoylamino.

Claim 14 (currently amended): ~~Use of a compound of formula (I), A method according to Claim 12 or 13~~Claim 16, for ~~use in the preparation of a pharmaceutical composition for the~~ treatment of a protein kinase dependent disease, especially one depending on ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the ALK, S6K1 or RET pathways or disease.

Claim 15 (original): A compound according to Claim 1, selected from the group consisting of:

[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(8-Thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
[4-(8-Benzofuran-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
2-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(8-Thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
2-[4-(8-Benzofuran-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
(4-Amino-3-chloro-phenyl)-acetonitrile;

{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;
 [3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 2-[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 2-{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;
 2-[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 [2-Fluoro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 [4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-2-fluoro-phenyl]-acetonitrile;
 {2-Fluoro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;
 2-[2-Fluoro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 2-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-2-fluoro-phenyl]-ethylamine;
 2-{2-Fluoro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;
 [3-Methyl-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 {4-[8-(1*H*-Indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-3-methyl-phenyl}-acetonitrile;
 2-[3-Methyl-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 2-{4-[8-(1*H*-Indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-3-methyl-phenyl}-ethylamine;
 (*R*)-2-Amino-3-[4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionamide;
 (*R*)-2-Amino-3-[4-(8-benzo[*b*]thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-
 propionamide;
 [3,5-Dichloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 [3,5-Dichloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 2-[3,5-Dichloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 2-[3,5-Dichloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 {4-[8-(4-Hydroxy-phenyl)-imidazo[4,5-*c*]quinolin-1-yl]-3-trifluoromethyl-phenyl}-acetonitrile;
 4-{1-[4-(2-Amino-ethyl)-2-trifluoromethyl-phenyl]-1*H*-imidazo[4,5-*c*]quinolin-8-yl}-phenol;
 3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(8-Benzo[*b*]thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(8-Thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(8-Thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;

3-[4-(8-Benzo[*b*]thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(8-Thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(8-Benzofuran-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-3-chloro-phenyl]-propionitrile;
 3-[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
 3-[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
 3-{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propionitrile;
 3-[4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-*c*]quinolin-1-yl)-3-chloro-phenyl]-propylamine;
 3-[3-Chloro-4-(8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
 3-[3-Chloro-4-(8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propylamine;
 3-{3-Chloro-4-[8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-propylamine;
 8-Benzo[1,3]dioxol-5-yl-1-{4-[2-(4,5-dihydro-1*H*-imidazol-2-yl)-ethyl]-phenyl}-1*H*-imidazo[4,5-*c*]quinoline;
 [3-Chloro-4-(2-methyl-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 [3-Chloro-4-(2-methyl-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 2-[3-Chloro-4-(2-methyl-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 2-[3-Chloro-4-(2-methyl-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 [4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 [4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 [4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 [4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 {4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-acetonitrile;
 [4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile;
 2-[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 2-[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 2-[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 2-[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 2-{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-*c*]quinolin-1-yl]-phenyl}-ethylamine;
 2-[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-ethylamine;
 3-[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-propionitrile;
 3-[4-(8-Benzo[1,3]dioxol-5-yl-7-fluoro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(7-Fluoro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(7-Fluoro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(8-Benzofuran-2-yl-7-fluoro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(8-Benzo[*b*]thiophen-2-yl-7-fluoro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-{4-[7-Fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-propylamine;
 [3-Chloro-4-(7-fluoro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
 [3-Chloro-4-(7-fluoro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
 {3-Chloro-4-[7-fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-acetonitrile;
 2-[3-Chloro-4-(7-fluoro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
 2-[3-Chloro-4-(7-fluoro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
 2-{3-Chloro-4-[7-fluoro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-ethylamine;
 [4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
 [4-(7-Chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
 [4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
 {4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-acetonitrile;
 [4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
 2-[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
 2-[4-(7-Chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
 2-[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
 2-{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-ethylamine;
 2-[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
 3-[4-(8-Benzo[1,3]dioxol-5-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-propionitrile;
 3-[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;

3-[4-(8-Benzo[1,3]dioxol-5-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(7-Chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-[4-(8-Benzofuran-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-{4-[7-Chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-propylamine;
 3-[4-(8-Benzo[*b*]thiophen-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 [3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
 [3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile;
 2-[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
 2-[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-ethylamine;
 3-[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-{3-Chloro-4-[7-chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-propionitrile;
 3-[3-Chloro-4-(7-chloro-8-thiophen-2-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-[3-Chloro-4-(7-chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propylamine;
 3-{3-Chloro-4-[7-chloro-8-(1*H*-indol-5-yl)-imidazo[4,5-c]quinolin-1-yl]-phenyl}-propylamine;
 3-[4-(2-Amino-7-chloro-8-thiophen-3-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(2-Amino-8-bromo-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 3-[4-(3-Amino-6-bromo-7-chloro-quinolin-4-ylamino)-phenyl]-propionitrile;
 3-[4-(2-Amino-8-benzofuran-2-yl-7-chloro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile;
 1-[4-(3-Amino-propyl)-phenyl]-7-chloro-8-thiophen-3-yl-1*H*-imidazo[4,5-c]quinolin-2-ylamine;
 1-[4-(3-Amino-propyl)-phenyl]-8-benzofuran-2-yl-7-chloro-1*H*-imidazo[4,5-c]quinolin-2-ylamine;
 8-(2,4-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-c]quinoline;
 8-(2,5-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-c]quinoline;
 8-(3,4-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-c]quinoline;
 1-(2-Fluoro-phenyl)-8-(3,4,5-trimethoxy-phenyl)-1*H*-imidazo[4,5-c]quinoline;
 8-(2,3-Dimethoxy-phenyl)-1-(2-fluoro-phenyl)-1*H*-imidazo[4,5-c]quinoline;
 1-(2-Fluoro-phenyl)-8-(2,3,4-trimethoxy-phenyl)-1*H*-imidazo[4,5-c]quinoline;
 1-(2-Fluoro-phenyl)-8-pyridin-4-yl-1*H*-imidazo[4,5-c]quinoline;
 1-(2-Fluoro-phenyl)-8-pyridin-3-yl-1*H*-imidazo[4,5-c]quinoline;
 1-(2-Fluoro-phenyl)-8-(3-methoxy-phenyl)-1*H*-imidazo[4,5-c]quinoline;

{3-[1-(2-Fluoro-phenyl)-1*H*-imidazo[4,5-*c*]quinolin-8-yl]-benzyl}-dimethyl-amine;
 1-(2-Fluoro-phenyl)-8-[3-(4-methyl-piperazin-1-ylmethyl)-phenyl]-1*H*-imidazo[4,5-*c*]quinoline;
 1-(2-Fluoro-phenyl)-8-(3-morpholin-4-ylmethyl-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;
 1-(2-Fluoro-phenyl)-8-(3-piperazin-1-ylmethyl-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;
 1-(2-Fluoro-phenyl)-8-(3-pyrrolidin-1-ylmethyl-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;
 1-Phenyl-8-(3-piperazin-1-yl-phenyl)-1*H*-imidazo[4,5-*c*]quinoline;
 8-(3-Fluoro-phenyl)-1-phenyl-1*H*-imidazo[4,5-*c*]quinoline;
 8-[3-(4-Methyl-piperazin-1-yl)-phenyl]-1-phenyl-1*H*-imidazo[4,5-*c*]quinoline;
 4-{1-[4-(4-Methyl-piperazin-1-yl)-phenyl]-1*H*-imidazo[4,5-*c*]quinolin-8-yl}-phenol;
 1-[4-(4-Methyl-piperazin-1-yl)-phenyl]-8-phenyl-1*H*-imidazo[4,5-*c*]quinoline; and
 [4-(8-Pyridin-4-yl-imidazo[4,5-*c*]quinolin-1-yl)-phenyl]-acetonitrile.

Claim 16 (new): The method according to Claim 10, wherein the protein kinase dependent disease is preferably one depending on PKB, ALK, S6K1 or RET and (especially aberrantly highly-expressed or activated) PKB, ALK, S6K1 or RET-dependent disease or disease dependent on the activation of the PKB, ALK, S6K1 or RET pathways, or a disease dependent on any combination thereof.